Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Computer-Aided Breast Cancer Detection in Women Undergoing Screening Mammography
This study is ongoing, but not recruiting participants.
Sponsored by: Aberdeen Royal Infirmary
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00450359
  Purpose

RATIONALE: A computer-aided detection program may help doctors find breast cancer sooner, when it may be easier to treat, in women undergoing screening mammography.

PURPOSE: This randomized clinical trial is studying how well computer-aided breast cancer detection works in women undergoing screening mammography.


Condition Intervention
Breast Cancer
Procedure: breast imaging study
Procedure: comparison of screening methods
Procedure: mammography

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer Mammography
U.S. FDA Resources
Study Type: Interventional
Study Design: Screening, Randomized
Official Title: A Prospective Evaluation of Computer Aided Detection (CAD) in the NHS Breast Screening Programme [CADET II]

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Breast cancer detection rate [ Designated as safety issue: No ]
  • Recall rate [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Film reader performance using computer-aided detection [ Designated as safety issue: No ]

Estimated Enrollment: 30000
Study Start Date: September 2006
Detailed Description:

OBJECTIVES:

  • Compare, prospectively, the breast cancer detection rate and recall rate of single reading using computer-aided detection vs standard double reading in women undergoing screening mammography.

OUTLINE: This is a prospective, randomized, multicenter study. Participants are randomized to 1 of 3 screening arms.

  • Arm I (double reading): Screening mammograms are independently reviewed by two readers (i.e., radiologist or radiographer), each of whom reports on any abnormalities and decides whether a participant is recalled for further assessment or returned home to routine screening. In the event there is disagreement between the readers' findings, a third reader acts as an arbitrator by rendering an interpretation of the mammogram and making the final decision to recall the participant or return to routine screening.
  • Arm II (single reading with computer-aided detection [CAD]): Screening mammograms are reviewed initially by a single reader who reports on any abnormalities. The reader then re-examines the mammogram with the aid of CAD, a system that uses computer prompts to recall suspicious features or abnormalities that may have been overlooked or previously dismissed as being normal. Based on these evaluations, a recommendation is made by the reader to either recall the participant for further assessment or return home to routine screening. If there is a discrepancy between the reader's interpretation and the CAD findings, another reader may be consulted to review the mammogram.
  • Arm III (double reading followed by single reading with CAD): Screening mammograms are reviewed by double reading as in arm I followed by single reading with CAD as in arm II.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 30,000 participants will be accrued for this study.

  Eligibility

Ages Eligible for Study:   50 Years to 70 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Currently undergoing 2-view mammography for routine breast cancer screening at any of the following participating National Health Services Breast Cancer Screening Program centers:

    • Manchester
    • Coventry
    • Nottingham
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Female
  • Menopausal status not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00450359

Locations
United Kingdom, England
Nottingham City Hospital NHS Trust
Nottingham, England, United Kingdom, NG5 1PB
Walsgrave Hospital
Coventry, England, United Kingdom, CV2 2DX
Withington Hospital
Manchester, England, United Kingdom, M20 8LR
United Kingdom, Scotland
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Sponsors and Collaborators
Aberdeen Royal Infirmary
Investigators
Study Chair: Fiona Gilbert, MD Aberdeen Royal Infirmary
  More Information

Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications of Results:
Study ID Numbers: CDR0000534404, ABROIN-06/MRE01/14, CRUK-CADET-II, ABROIN-CADET-II, EU-20709
Study First Received: March 20, 2007
Last Updated: October 28, 2008
ClinicalTrials.gov Identifier: NCT00450359  
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
breast cancer

Study placed in the following topic categories:
Skin Diseases
Breast Neoplasms
Breast Diseases
Coronary Artery Disease

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009